Navigation Links
PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
Date:9/21/2012

LEIPZIG, Germany and NES-ZIONA, Israel, Sept. 21, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that data from the company's Phase II trial of hGH-CTP, its long acting human growth hormone, in growth hormone deficient adults will be presented at ESPE 2012, the 51st Annual Meeting of the European Society for Paediatric Endocrinology. 

The previously reported data confirmed that a single weekly injection of hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone from the current standard of one injection per day to a single weekly injection.  In this trial, hGH-CTP demonstrated a good safety and tolerability profile.  In addition, the study showed that only 50-65% of the cumulative weekly dose of conventional human growth hormone was required for the majority of the patients to remain within the normal range of IGF-1, a key biomarker of growth hormone activity.  The safety profile of hGH-CTP in this trial was further enhanced by the finding that it did not cause excessive IGF-1 levels in patients, nor was any IGF-I accumulation observed.

The positive Phase II data in adults were instrumental in PROLOR's decision to proceed with a Phase II hGH-CTP trial in growth hormone deficient children that is currently enrolling patients.  The pediatric Phase II trial is a randomized, open-label, dose-finding study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamic properties of hGH-CTP injected weekly in children with growth hormone deficiency.  The trial is comparing the 12-month growth velocity of children receiving hGH-CTP injected once weekly with those receiving commercially available hGH injected daily.

"Growth hormone replacement therapy may enable a growth hormone deficient child to reach a normal height, but it currently involves daily dosing that may total more than 3,000 injections before the child reaches t
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
2. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
3. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
4. Air Products to Feature Medical and Industrial Grade Gas Solutions for Pharma, Biotech, and Life Science Applications at Mid-Atlantic Bio Conference
5. Biotech Executive Salaries Continue to Rise Despite Weak Economy
6. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
7. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
8. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
9. Germany Prioritizes Medical Biotechnology with New Initiatives
10. Why Texas is #1 in Business: Local BioTech Company Expands
11. RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... 10, 2014   Ceres, Inc . (Nasdaq: ... announced today financial results for the three months ended ... business. Ceres reported that the company and ... this growing season in Brazil, which concluded in June, ... sorghum evaluation areas for part of the growing season. ...
(Date:7/10/2014)... been extremely challenging because there are many genetic variants ... disease. Now investigators reporting in the July 3rd issue ... describe a strategy that may help reveal how ... or environmental exposures to affect the development of the ... may predispose individuals to schizophrenia. , The work ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2
... ... ... conservation, better materials for frontier technologies and new economic engines, and breakthroughs in understanding diseases: ... enabled by an upgrade to the Advanced Photon Source (APS) at the U.S. Department of ...
... BANGALORE, India , May 3 The Global ... today at the 2010 BIO International Convention that they have ... development and clinical use of drugs against tuberculosis (TB), including ... with TB are resistant to at least one of today,s ...
... , May 3 The American College ... American Gastroenterological Association (AGA)Institute today announced an innovative initiative ... at Digestive Disease Week ® 2010.  The peer-driven campaign ... lines of the diagnosis and treatment of hereditary angioedema ...
Cached Biology Technology:Upgrade to Advanced Photon Source Announced by DOE 2Upgrade to Advanced Photon Source Announced by DOE 3Upgrade to Advanced Photon Source Announced by DOE 4TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 2TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 4ACAAI and AGA Partner to Raise Awareness of Hereditary Angioedema Through 'HAE: Learn About It, Talk About It' 2ACAAI and AGA Partner to Raise Awareness of Hereditary Angioedema Through 'HAE: Learn About It, Talk About It' 3ACAAI and AGA Partner to Raise Awareness of Hereditary Angioedema Through 'HAE: Learn About It, Talk About It' 4ACAAI and AGA Partner to Raise Awareness of Hereditary Angioedema Through 'HAE: Learn About It, Talk About It' 5
(Date:7/11/2014)... Bone and Mineral Research awarded Michael F. Holick, PhD, ... the 2014 Louis V. Avioli Award. Holick, a professor ... known for revolutionizing the understanding of vitamin D and ... honors a member of the American Society for Bone ... and mineral basic research. It is named for ASBMR,s ...
(Date:7/11/2014)... set a "mouse TRAP" to capture the early signs ... published in the Journal of Clinical Investigation . ... TRAP to extract cellular and genetic information from a ... the Rockefeller Institute for Medical Research in 2008, TRAP ... or ribosomes, of the cell type of interest. Scientists ...
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... 2012) Researchers have gained new insight into why ... achieving a folate concentration considered optimal for reducing the risk ... absence of folate deficiency in the general Canadian population. ... main reason why some women are not achieving levels optimal ...
... Diego, CA, April 10, 2012 The neighborhoods in which ... role in whether or not they eat a healthy diet, ... studies in a special theme issue of the American ... six studies uses the latest concepts and methods in geographic ...
... Boston, MA Meningioma, the most common primary brain ... percent of all primary brain tumors. The most consistently ... ionizing radiation. In the largest study of its ... University School of Medicine, Duke University, UCSF and Baylor ...
Cached Biology News:Geographic information systems demonstrate links between health and location 2Dental X-rays linked to common brain tumor 2
... MEGAscript RNAi Kit is optimized ... mass amounts of ready-to-use dsRNA ... systems. The MEGAscript RNAi Kit ... high-yield transcription technol-ogy and includes ...
... actuators as building blocks, Parker can ... ,robotic solutions that are ideal for ... base ,system, Parker can also integrate ... structures, and ,guarding., Standard or ...
... is the smallest electronic pressure controller available ... Parker configured this unit specifically for the ... Used in carrier gas flow control, microfluidic ... and hydro-dynamic focusing, the OEM-EPC offers external ...
...
Biology Products: